Atossa Genetics (NASDAQ:ATOS) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.
Separately, Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of Atossa Genetics in a research note on Wednesday, January 9th.
Shares of ATOS stock opened at $7.07 on Friday. Atossa Genetics has a fifty-two week low of $0.80 and a fifty-two week high of $7.56.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.